NEW YORK (GenomeWeb News) – Interleukin Genetics said Friday that it has received notification from the New York  Stock Exchange Alternext that the firm is not in compliance with certain listing criteria.

Specifically, the firm’s stockholders' equity is less than $6 million and it has reported losses from continuing operations and net losses in its five most recent fiscal years.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.